Table 1.
The baseline and clinical characteristics
| Guangzhou training cohort | Guangzhou validation cohort | |||||
|---|---|---|---|---|---|---|
|
Patients (n = 843) |
Low risk (n = 716) |
High risk (n = 127) |
Patients (n = 212) |
Low risk (n = 172) |
High risk (n = 40) |
|
| Age (y) | ||||||
| <45 | 365 | 311 (85.2%) | 54 (14.8%) | 101 | 81 (80.2%) | 20 (19.8%) |
| ≥45 | 478 | 405 (84.7%) | 73 (15.3%) | 111 | 91 (82.0%) | 20 (18.0%) |
| Sex | ||||||
| Male | 628 | 528 (84.1%) | 100 (15.9%) | 151 | 120 (79.5%) | 31 (20.5%) |
| Female | 215 | 188 (87.4%) | 27 (12.6%) | 61 | 52 (85.2%) | 9 (14.8%) |
| T stage | ||||||
| T1 | 89 | 77 (86.5%) | 12 (13.5%) | 28 | 24 (85.7%) | 4 (14.3%) |
| T2 | 133 | 116 (87.2%) | 17 (12.8%) | 21 | 15 (71.4%) | 6 (28.6%) |
| T3 | 398 | 351 (88.2%) | 47 (11.8%) | 109 | 90 (82.6%) | 19 (17.4%) |
| T4 | 223 | 172 (77.1%) | 51 (22.9%) | 54 | 43 (79.6%) | 11 (20.4%) |
| N stage | ||||||
| N0 | 89 | 82 (92.1%) | 7 (7.9%) | 21 | 18 (85.7%) | 3 (14.3%) |
| N1 | 326 | 291 (89.3%) | 35 (10.7%) | 88 | 74 (84.1%) | 14 (15.9%) |
| N2 | 276 | 220 (79.7%) | 56 (20.3%) | 63 | 52 (82.5%) | 11 (17.5%) |
| N3 | 152 | 123 (80.9%) | 29 (19.1%) | 40 | 28 (70.0%) | 12 (30.0%) |
| TNM stage | ||||||
| I | 22 | 20 (90.9%) | 2 (9.1%) | 8 | 6 (75.0%) | 2 (25.0%) |
| II | 110 | 100 (90.9%) | 10 (9.1%) | 19 | 16 (84.2%) | 3 (15.8%) |
| III | 369 | 324 (87.8%) | 45 (12.2%) | 100 | 85 (85.0%) | 15 (15.0%) |
| IV | 342 | 272 (79.5%) | 70 (20.5%) | 85 | 65 (76.5%) | 20 (23.5%) |
| EBVDNA copies | ||||||
| <1000 | 326 | 288 (88.3%) | 38 (11.7%) | 96 | 76 (79.2%) | 20 (20.8%) |
| 1000‐9999 | 229 | 203 (88.6%) | 26 (11.4%) | 54 | 49 (90.7%) | 5 (9.3%) |
| 10 000‐99 999 | 206 | 162 (78.6%) | 44 (21.4%) | 44 | 32 (72.7%) | 12 (27.3%) |
| 100 000‐999 999 | 72 | 55 (76.4%) | 17 (23.6%) | 15 | 13 (86.7%) | 2 (13.3%) |
| >1 000 000 | 10 | 8 (80.0%) | 2 (20.0%) | 3 | 2 (66.7%) | 1 (33.3%) |
| Hemoglobin concentration (g/L) | ||||||
| <120 | 51 | 43 (84.3%) | 8 (15.7%) | 7 | 6 (85.7%) | 1 (14.3%) |
| ≥120 | 792 | 673 (85.0%) | 119 (15.0%) | 205 | 166 (81.0%) | 39 (19.0%) |
| LDH concentration（U/L） | ||||||
| ＜245 | 753 | 645 (85.7%) | 108 (14.3%) | 185 | 149 (80.5%) | 36 (19.5%) |
| ≥245 | 90 | 71 (78.9%) | 19 (21.1%) | 27 | 23 (85.2%) | 4 (14.8%) |
| Treatment method | ||||||
| RT alone | 67 | 61 (91.0%) | 6 (9.0%) | 0 | 0 | 0 |
| CCRT | 279 | 222 (79.6%) | 57 (20.4%) | 55 | 38 (69.1%) | 17 (30.9%) |
| ICT + CCRT | 492 | 428 (87.0%) | 64 (13.0%) | 137 | 118 (86.1%) | 19 (13.9%) |
| CCRT + ACT | 5 | 5 (100%) | 0 (0) | 20 | 16 (80.0%) | 4 (20.0%) |
Abbreviations: ACT, adjuvant chemotherapy; CCRT, concurrent chemoradiotherapy; EBVDNA, Epstein‐Barr virus DNA; ICT, induction chemotherapy; LDH, serum lactate dehydrogenase levels; RT, radiotherapy.